Department of Dermatology at Kyorin University School of Medicine, Shinkawa, Mitaka, Tokyo, Japan.
Department of Dermatology at Kyorin University School of Medicine, Shinkawa, Mitaka, Tokyo, Japan; Department of Dermatology, Saitama Medical University, Saitama Medical Center, Kawagoe, Saitama, Japan.
J Am Acad Dermatol. 2019 Mar;80(3):670-678.e2. doi: 10.1016/j.jaad.2018.08.052. Epub 2018 Sep 18.
The prognosis of drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS) is highly unpredictable. Severe complications, either related or unrelated to cytomegalovirus (CMV) reactivation, are a highly probable cause of death.
The aim was to establish a scoring system for DiHS/DRESS that can be used to monitor severity, predict prognosis, and stratify the risk of developing CMV disease and complications.
A retrospective analysis of 55 patients with DiHS/DRESS was performed. A composite score was created using clinical data. DiHS/DRESS patients were also stratified into 3 groups based on the scores to predict the risk of CMV reactivation and complications.
This scoring system made it possible to predict CMV disease and complications. Scores ≥4 were associated with the later development of CMV disease and complications, while no patients with scores <4 developed complications.
This was a single-institution study with a relatively small patient cohort that lacked a validation cohort.
Our scoring system may be useful for predicting CMV-related complications, and early intervention with anti-CMV agents should be considered in patients with scores ≥4 or with evidence of CMV reactivation.
药物诱导的超敏反应综合征(DIHS)/药物反应伴嗜酸性粒细胞增多和全身症状(DRESS)的预后极难预测。严重并发症,无论是与巨细胞病毒(CMV)再激活相关还是不相关,都是导致死亡的高度可能原因。
建立一个可用于监测严重程度、预测预后以及分层 CMV 疾病和并发症风险的 DIHS/DRESS 评分系统。
对 55 例 DIHS/DRESS 患者进行回顾性分析。使用临床数据创建了一个综合评分。根据评分将 DIHS/DRESS 患者分为 3 组,以预测 CMV 再激活和并发症的风险。
该评分系统可预测 CMV 疾病和并发症。评分≥4 与 CMV 疾病和并发症的后期发展相关,而评分<4 的患者均未发生并发症。
这是一项单中心研究,患者队列相对较小,缺乏验证队列。
我们的评分系统可能有助于预测 CMV 相关并发症,对于评分≥4 或有 CMV 再激活证据的患者,应考虑早期使用抗 CMV 药物进行干预。